Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alethia Biotherapeutics, a Canada-based biotechnology company, has announced a $2.2 million investment. This financing was led GO Capital Fund and BDC Venture Capital. Epicentre Technologies and Alethia founders, Yves Cornellier and Mario Filion, also participated in this internal round of financing.
Subscribe to our email newsletter
Yves Cornellier, president and CEO of Alethia, said: “We are thankful for the continuous support of GO Capital, BDC Venture Capital and Epicentre Technologies. This new investment will be used to advance the development of Alethia’s portfolio of therapeutic monoclonal antibodies.
“These funds represent the first step towards the closing of a presently evolving series A round that will help bring our lead therapeutics into the clinic. Furthermore, this investment will allow us to further explore the potential of our programs to maximize their value for partnership opportunities.”